Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Tetra Bio-Pharma Provides Update on Research Collaboration

<< Previous

Bullboard Posts

Next >>

Post by Betteryear2on Mar 08, 2022 7:20am

208 Views

Post# 34494006

Tetra Bio-Pharma Provides Update on Research Collaboration

Health Canada approved the amendment of the phase I study to assess the effect of low and moderate doses of inhaled CBD in healthy cannabinoid users.
The collaboration with the CRCHUM will allow Tetra to obtain phase I clinical data on inhaled CBD.

OTTAWA, ON, March 8, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that Health Canada approved the amendment of a phase I study conducted in collaboration with Dr. Jutras-Aswad and the University of Montreal Hospital Research Centre (Centre de recherche du Centre hospitalier de l'Universit de Montral, ("CRCHUM"). The study will assess the safety profile of low and moderate doses of inhaled CBD and determine the cognitive, behavioral, and biological effects of CBD in adults who occasionally use cannabis. The clinical trial has been authorized by Health Canada, who also recently approved an amendment to the research protocol to increase the dosage of the study drug up to 100 mg of CBD to be assessed in the study.